Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Viking Therapeutics (GB:0VQA)
LSE:0VQA
Viking Therapeutics (0VQA) Share Price & Analysis
9 Followers
0VQA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.88 - $99.30
Previous Close$66.42
Volume7.49K
Average Volume (3M)13.03K
Market Cap
$7.10B
Enterprise Value$6.14B
Total Cash (Recent Filing)$962.98M
Total Debt (Recent Filing)$1.18M
Price to Earnings (P/E)N/A
Beta2.12
Next Earnings
Jul 24, 2024EPS Estimate
-$0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding100,488,339
10 Day Avg. Volume48
30 Day Avg. Volume13,031
Standard Deviation0.21
R-Squared0.30
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)18.77
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-92.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-392.90
Forecast
1Y Price Target
$113.50Price Target Upside69.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Viking Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressWith plans to engage the FDA for future study designs, Viking demonstrates progression in their drug development pipeline, signaling potential for accelerated growth.
Drug EfficacyViking's VK2809 shows promise with its potent effectiveness, potentially outshining competitors in the NASH treatment market.
Financial StabilityViking boasts a strong cash position, ensuring the company can sustain its clinical trials and support its research and development efforts.
Bears Say
Clinical Trial RisksIf VKTX's treatments show less than expected body weight loss, there's a significant risk of the stock value decreasing substantially.
Drug Efficacy ConcernsWith Novo Nordisk's recent amycretin data, there is potential for a revision in the weight loss benchmark for VK2735.
Regulatory ChallengesViking may need to conduct multiple, multi-year, potentially very expensive studies for NASH approval.
---
Options Prices
Currently, No data available
---
Ownership Overview
8.95% Insiders
25.45% Mutual Funds
13.41% Other Institutional Investors
52.19% Public Companies and
Individual Investors
0VQA FAQ
What was Viking Therapeutics’s price range in the past 12 months?
Viking Therapeutics lowest share price was $8.88 and its highest was $99.30 in the past 12 months.
What is Viking Therapeutics’s market cap?
Currently, no data Available
When is Viking Therapeutics’s upcoming earnings report date?
Viking Therapeutics’s upcoming earnings report date is Jul 24, 2024 which is in 86 days.
How were Viking Therapeutics’s earnings last quarter?
Viking Therapeutics released its earnings results on Apr 24, 2024. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.277 by $0.017.
Is Viking Therapeutics overvalued?
According to Wall Street analysts Viking Therapeutics’s price is currently Undervalued.
Does Viking Therapeutics pay dividends?
Viking Therapeutics does not currently pay dividends.
What is Viking Therapeutics’s EPS estimate?
Viking Therapeutics’s EPS estimate is -$0.27.
How many shares outstanding does Viking Therapeutics have?
Viking Therapeutics has 109,356,290 shares outstanding.
What happened to Viking Therapeutics’s price movement after its last earnings report?
Viking Therapeutics reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.277. Following the earnings report the stock price went up 1.396%.
Which hedge fund is a major shareholder of Viking Therapeutics?
Among the largest hedge funds holding Viking Therapeutics’s share is Viking Global Investors LP. It holds Viking Therapeutics’s shares valued at 96M.
---
Viking Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$113.50 (69.51% Upside)
$113.50 (69.51% Upside)
Blogger Sentiment
Bullish
GB:0VQA Sentiment 93%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
246.37%
12-Months-Change
Fundamentals
Return on Equity
-17.55%
Trailing 12-Months
Asset Growth
541.19%
Trailing 12-Months
Company Description
Viking Therapeutics
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company's clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
---
0VQA Earnings Call
Q1 2024
0:00 / 0:00
---
0VQA Stock 12 Months Forecast
Average Price Target
$113.50
▲(69.51% Upside)
Technical Analysis
Best Analysts Covering 0VQA
1 Year
1 Year Success Rate
13/14 ratings generated profit
1 Year Average Return
+249.84%
reiterated a buy rating 4 days ago
Copying Naz Rahman's trades and holding each position for 1 Year would result in 92.86% of your transactions generating a profit, with an average return of +249.84% per trade.
---